

Date: February 09, 2026

To,

National Stock Exchange of India Limited

Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (East), Mumbai – 400051
Maharashtra, India.

Symbol: FABTECH

BSE Limited

Listing Department
Floor 25, P J Towers,
Dalal Street, Mumbai – 400001
Maharashtra, India.

Scrip Code: 544558

Dear Sir/Madam,

Sub: Investor Presentation

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Investor Presentation in relation to the Unaudited Financial Results for the quarter and nine-months ended December 31, 2025.




Request you to take the same on record.

Thank you.

**Yours faithfully,
For Fabtech Technologies Limited**

Hemant Mohan Anavkar
Executive Director
DIN: 00150776

Encl.: As mentioned above



Fabtech[®]
Technologies Limited
Life Engineering[™]

Fabtech Technologies Limited

December 2025 Investor Presentation

This presentation and the accompanying slides (the “Presentation”), which have been prepared by Fabtech Technologies Limited, (The Company) solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantee of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict.

These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks.

The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.

Why Turnkey + In-House Manufacturing Matters

- In pharmaceutical, biopharma, and healthcare projects, choosing a turnkey partner with in-house **Process, Air & Water** manufacturing capabilities is no longer a preference, it's a strategic necessity.
- **Single Accountability, Zero Coordination Risk:** One partner owns design, engineering, manufacturing, installation, and validation eliminating delays and vendor conflicts.
- **Precision-Controlled Environments In-House:** Process Equipment & Containment Systems (Process), Cleanrooms (Air) & Purified Water & Distribution (Water) are engineered under one ecosystem ensuring seamless integration and regulatory compliance.
- **Speed to Market:** In-house manufacturing drastically reduces dependency on imports and fragmented suppliers accelerating delivery, qualification, and commercial launch.
- **Regulatory Confidence:** A unified turnkey approach ensures every system meets global cGMP, WHO, EU-GMP, USFDA, and ISO standards from the first blueprint to final validation.
- **Cost Efficiency & Long-Term Reliability:** Integrated design-to-delivery reduces project cost overruns and safeguards long-term operational efficiency.



Fabtech

Fabtech Technologies Limited (FTL), the flagship of the Fabtech Group, brings three decades of engineering excellence to deliver **start-to-finish** (turnkey solutions) for pharmaceutical, biotech, and healthcare facilities worldwide. With deep capabilities across **Process, Air & Water**, FTL integrates design, engineering, manufacturing, and validation to build GMP-compliant, energy-efficient, and contamination-controlled environments across **62 countries**.

Post-COVID, the MEA region's focus on pharmaceutical self-reliance has accelerated FTL's growth trajectory. Deriving **78% of revenue from MENA, GCC, and ECO Zone markets**, the Company expands through **FTS Cleanroom Systems LLC** and strategic joint ventures. With **20 secured projects worth ₹13,724.61 lakhs**, FTL continues to strengthen its position as a preferred partner for critical facility infrastructure.

Fabtech's asset-light, integrated model combines in-house manufacturing, advanced project execution, and minimal third-party dependency to ensure **speed, quality, and consistency**. By mastering the pillars of **Precision Process Systems, Bio-Clean Air, and Pure Water**, FTL empowers nations to build **resilient, sustainable, and future-ready healthcare manufacturing ecosystems**.



Key Facts & Figures



ISO-Certified
Operations



180+
Team Size Including
94+
Qualified Engineers



Start-To-Finish
Turnkey
Engineering Solutions
Provider



₹ 98,305 Lakhs
Order Book As of
03rd November 2025



Turnkey Design
Build-Execute
Expert



Presence in **62 Countries**
with
Global operations in
cleanrooms, HVAC, process and
automation



3 Decades of
Fabtech Group's
Legacy



Trusted By **Leading**
Pharmaceutical & Biotech
Companies

9M (April'25 – Dec'25) FY26 Financials


₹ 26,309.11 Lakhs
Total Income

₹ 2,390.12 Lakhs
EBITDA

₹ 1,630.23 Lakhs
Net Profit

Turnkey Engineering Solutions: Driving Efficiency Across the Value Chain

How FABTECH Fits




Capex earmarked by pharmaceutical companies

Experienced turnkey engineering solution providers ensure successful completion/ upgrade of capex projects

Increased capabilities of pharmaceutical companies through optimal utilisation of capex

From Advisory to Post-Compliance Support: Start-to-End Services Covering the Entire Project Value Chain

— Fabtech Group: A Structured Legacy of Engineering Excellence



*Pursuant to TSA Share Purchase Agreement, Thermax Limited acquired 51% of equity share capital of our erstwhile associate company, TSA Process Equipments Private Limited ("TSA") and finalised the terms of acquisition of the remaining 49% in a staged manner spanning over a period of two years.

9M (April'25 – Dec'25) FY26 Result Highlights

(₹ Lakhs)

Particulars	9M FY26 (April'25 – Dec'25)	9M FY25 (April'25 – Dec'25)	YoY Change
Total Income	26,309.11	19,811.85	32.79%
EBITDA	2,390.12	4,348.95	(45.04%)
EBITDA Margin (%)	9.08%	21.95%	
Net profit for the Period	1,630.23	3,136.18	(48.02%)
Net Profit Margin (%)	6.20%	15.83%	
EPS (₹)	4.49	9.68	(53.62%)

Deployment & Utilization Of Issue Proceeds

(In ₹ Lakhs)

Objects of the Issue (as per Prospectus)	Amount as per Offer Document (A)	Amount Utilised – As at Beginning of the Quarter (B)	Amount Utilised – During the Quarter (C)	Amount Utilised – As at End of the Quarter (B + C)	Unutilised Amount (A – B – C)
Working Capital Requirement	12,700.00	–	–	–	12,700.00
Inorganic Growth Initiatives through Acquisitions	3,000.00	–	–	–	3,000.00
General Corporate Purposes	5,052.02	–	125.00	125.00	4,927.02
Estimated Issue Expenses	2,277.63	–	2,225.25	2,225.25	52.38
Total	23,029.65	–	2,350.25	2,350.25	20,679.40

WE ARE COMMITTED TO SAVING LIVES



Fabtech Technologies Limited

Registered Office: 715, Janki Center, Off Veera Desai Road, Andheri West, Mumbai 400 053, Maharashtra, India

Phone: +91 226 159 2900

Corporate Office: 1st Floor, ABR Emerald, Plot No D8, Street 16, MIDC Andheri East, Chakala MIDC, Mumbai – 400 093, Maharashtra, India.

Phone: +91 226 554 0300

Email: cs@fabtechnologies.com

Website: www.fabtechnolgies.com



AKMIL Strategic Advisors Private Limited

Address: Office No. 1011, 10th Floor, Opal Square, Road No. 16, Wagle Estate, Thane (w)-400 604, Maharashtra, India

Phone: +91 98209 41925

Email: info@akmiladvisors.com

Website: www.akmiladvisors.com

THANK YOU